Anti-Lethal Therapy of COVID-19 for Home Health Outpatient Therapy



Abstract Views
1526

Downloads
559

Citations

Share

##plugins.themes.bootstrap3.article.sidebar##

Submitted Jun 30, 2021
Published Jul 23, 2021
10.24018/ejmed.2021.3.4.960

Abstract viewed = 1526 times

Table of Contents

##plugins.themes.bootstrap3.article.main##

The article presents the rationale for a new therapeutic strategy for treatment of patients with COVID-19, based on the combined use of biologic response modifiers and drugs targeting etiology and pathophysiology of the novel coronavirus infection, excluding disadvantages of polypharmacy, and providing a high clinical effect. This approach has been predominantly used in home health outpatient treatment of 324 patients with COVID-19 of variable severity using the biologic response modifiers “double drug cocktail” made of recombinant human interleukin-2 and recombinant human interferon alpha-2b in combination with alimemazine, nimesulide, rivaroxaban and antibiotic therapy (co-amoxiclav, or ceftriaxone) if secondary bacterial pneumonia was diagnosed. The results obtained indicate a dramatic improvement in the condition of patients, even with a severe COVID-19, which made possible to avoid artificial ventilation and prevent deaths.

Keywords: Anti-lethal therapy, COVID-19, Cytokines, Interleukin-2, Interferon alpha-2b, Outpatient treatment

Downloads

Download data is not yet available.

References

  1. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int Date: June 30, 2021. Date accessed: June 30, 2021.
     Google Scholar
  2. RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:605–612.
     Google Scholar
  3. Aygün İ, Kaya M, Alhajj R. Identifying side effects of commonly used drugs in the treatment of Covid 19. Sci Rep. 2020;10:21508.
     Google Scholar
  4. Dai S-P, Zhao X, Wu J-H. Effects of comorbidities on the elderly patients with COVID-19: clinical characteristics of elderly patients infected with COVID-19 from Sichuan, China. J Nutr Health Aging. 2021;25:18–24.
     Google Scholar
  5. Pavlenko S.M. Pathogenesis and sanogenesis of disease. Ter Arkh. 1965;37(in Russian):115–122.
     Google Scholar
  6. Ashraf UM, Abokor AA, Edwards JM, et al. SARS-CoV-2, ACE2 expression, and systemic organ invasion. Physiol Genomics. 2021;53:51–60.
     Google Scholar
  7. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020;71:762–768.
     Google Scholar
  8. Mangalmurti N, Hunter CA. Cytokine storms: understanding COVID-19. Immunity. 2020;53:19–25.
     Google Scholar
  9. Khan S, Siddique R, Shereen MA, et al. Emergence of a novel coronavirus, severe acute respiratory syndrome coronavirus 2: biology and therapeutic options. J Clin Microbiol. 2020;58:e00187–20.
     Google Scholar
  10. Kupferschmidt K, Cohen J. Race to find COVID-19 treatments accelerates. Science. 2020;367:1412–1413.
     Google Scholar
  11. Kouznetsov VV. COVID-19 treatment: much research and testing, but far, few magic bullets against SARS-CoV-2 coronavirus. Eur J Med Chem.2020;203:112647.
     Google Scholar
  12. Vougogiannopoulou K,Corona A, Tramontano E, Alexis MN, Skaltsounis A-L. Natural and nature-derived products targeting human coronaviruses. Molecules. 2021;26:448.
     Google Scholar
  13. National Institutes of Health. Characteristics of immunomodulators under evaluation for the treatment of COVID-19. https://www.covid19treatmentguidelines.nih.gov/tables/table-4b Date: February 21, 2021. Date accessed: April 05, 2021.
     Google Scholar
  14. Bernasconi S. Low dose medicine: theoretical background and scientific evidence. Ital J Pediatr. 2018;44:23.
     Google Scholar
  15. Ratheesh M, Sheethal S, Jose SP, et al. Biochemical and immunological aspects of COVID-19 infection and therapeutical intervention of oral low dose cytokine therapy: a systematic review. Immunopharmacol Immunotoxicol. 2021;43:22–29.
     Google Scholar
  16. Kelly E, Won A, Refaeli Y, Van Parijs L. IL-2 and related cytokines can promote T cell survival by activating AKT. J Immunol. 2002;168: 597–603.
     Google Scholar
  17. Bo Diao CW, Tan Y, Chen X, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol.2020;11:1–7.
     Google Scholar
  18. Ehrenfeld M, Tincani A, Andreoli L, et al. Covid-19 and autoimmunity. Autoimmun Rev. 2020;19:102597.
     Google Scholar
  19. Sakaguchi S, Miyara M, Costantino CM, et al. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol. 2010;10:490–500.
     Google Scholar
  20. Spence A, Klementowicz JE, Bluestone JA, Tang Q. Targeting Treg signaling for the treatment of autoimmune diseases. Curr Opin Immunol. 2015;37:11–20.
     Google Scholar
  21. Wei LL, Wang WJ, Chen DX, Xu B. Dysregulation of the immune response affects the outcome of critical COVID-19 patients. J Med Virol.2020;92:2768–2776.
     Google Scholar
  22. YuA, SnowhiteI, VendrameF, et al. Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes. Diabetes. 2015;64:2172–2183.
     Google Scholar
  23. Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12:180–190.
     Google Scholar
  24. YazanA.Interleukin-2 level for normal people and COVID-19 infection: is it our concern is COVID-19 infection or interleukin-2 level before the infection? EJMO. 2021;5:1–5.
     Google Scholar
  25. Zhu M-E, Wang Q, Zhou S, Wang B, Ke L, He P. Recombinant interleukin-2 stimulates lymphocyte recovery in patients with severe COVID-19. Exp Ther Med. 2021;21:227.
     Google Scholar
  26. Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T cells and immune tolerance. Cell. 2008;133:775–787.
     Google Scholar
  27. Teijaro JR. Type I interferons in viral control and immune regulation. Curr. Opin. Virol.2016;16:31–40.
     Google Scholar
  28. El-LababidiRM, MootyM, BonillaM-F, SalemNM. Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a. IDCases. 2020;21:e00837.
     Google Scholar
  29. Acharya D, Liu G, Gack MU. Dysregulation of type I interferon responses in COVID-19. Nat Rev Immunol. 2020;20:397–398.
     Google Scholar
  30. MeffreE, Iwasaki A. Interferon deficiency can lead to severe COVID. Nature. 2020;587:374–376.
     Google Scholar
  31. Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584:463–469.
     Google Scholar
  32. Agrawal A. Mechanisms and implications of age-associated impaired innate interferon secretion by dendritic cells: a mini-review. Gerontology. 2013;59:421–426.
     Google Scholar
  33. Mantlo E, Bukreyeva N, Maruyama J, Paessler S, Huang C. Antiviral activities of type I interferons to SARS-CoV-2 infection. Antiviral Res.2020;179:104811.
     Google Scholar
  34. Felgenhauer U, Schoen A, Gad HH, et al. Inhibition of SARS-CoV-2 by type I and type III interferons. J Biol Chem. 2020;295:13958–13964.
     Google Scholar
  35. Landowski CP, Mustalahti E, Wahl R. Enabling low cost biopharmaceuticals: high level interferon alpha-2b production in Trichoderma reesei. Microb Cell Fact. 2016;15:104.
     Google Scholar
  36. Ziegler CGK, Allon SJ, Nyquist SK, et al. SARS-CoV-2 receptor ACE2 is an interferon stimulated gene in human airway epithelial cells and is enriched in specific cell subsets across tissues. Cell. 2020;181:1016–1035.e19.
     Google Scholar
  37. Yoshikawa T, Hill TE, Yoshikawa N, et al. Dynamic innate immune responses of human bronchial epithelial cells to severe acute respiratory syndrome-associated coronavirus infection. PLoS One. 2010;5:e8729.
     Google Scholar
  38. Zhou Q, Chen V, Shannon CP, et al. Interferon-α2b treatment for COVID-19. Front Immunol. 2020;11:1061.
     Google Scholar
  39. Baden LR, Rubin EJ. Covid-19 – the search for effective therapy. N Engl J Med. 2020;382:1851–1852.
     Google Scholar
  40. TanchevaL, Petralia MC, MitevaS. Emerging neurological and psychobiological aspects of COVID-19 infection. Brain Sci. 2020;10:852.
     Google Scholar
  41. Steardo LJr, Steardo L, Verkhratsky A. Psychiatric face of COVID-19. Transl Psychiatry. 2020;10:261.
     Google Scholar
  42. Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: a systematic review and meta-analysis. Rev Med Virol.2020;30:1–9.
     Google Scholar
  43. Tsatsakis A, Calina D, Falzone L. SARS-CoV-2 pathophysiology and its clinical implications: An integrative overview of the pharmacotherapeutic management of COVID-19. Food Chem Toxicol. 2020;146:111769.
     Google Scholar
  44. Nicholls AJ, Wen SW, Hall P, Hickey MJ, Wong CHY. Activation of the sympathetic nervous system modulates neutrophil function. J Leukoc Biol.2018;103:295–309.
     Google Scholar
  45. Del Rio R, Marcus NJ, Inestrosa NC. Potential role of autonomic dysfunction in Covid-19 morbidity and mortality. Front Physiol.2020;11:561749.
     Google Scholar
  46. Shah RM, Shah M, Shah S, Li A, Jauhar S. Takotsubo syndrome and COVID-19: associations and implications. Curr Probl Cardiol. 2021;46:100763.
     Google Scholar
  47. Sloan EK, Priceman SJ, Cox BF, et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Research. 2010;70:7042–7052.
     Google Scholar
  48. L, Pei R-j, Li H, et al. Identification of SARS-CoV-2 entry inhibitors among already approved drugs. Acta Pharmacol Sin. 2020; (published online Oct 28.) https://doi.org/10.1038/s41401-020-00556-6.
     Google Scholar
  49. GodinoC, ScottiA, MaugeriN, et al. Antithrombotic therapy in patients with COVID-19? - Rationale and evidence. Int J Cardiol. 2021;324:261–266.
     Google Scholar
  50. Scalise M, Indiveri C. Repurposing Nimesulide, a potent inhibitor of the B0AT1 subunit of the SARS-CoV-2 receptor, as a therapeutic adjuvant of COVID-19.SLAS Discov. 2020;25:1171–1173.
     Google Scholar
  51. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England). 2020;395:1054–1062.
     Google Scholar
  52. Sieswerda E, de Boer MGJ, Bonten MMJ, et al. Recommendations for antibacterial therapy in adults with COVID-19 – an evidence based guideline. Clin Microbiol Infect. 2021;27: 61–66.
     Google Scholar
  53. Greenhalgh T, Knight M, A’Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026.
     Google Scholar
  54. Moreno-Pérez O, Merino E, Leon-Ramirez J-M, et al. Post-acute COVID-19 syndrome. incidence and risk factors: a Mediterranean cohort study. J Infect. 2021;82:378–383.
     Google Scholar
  55. Boyman O, Létourneau S, Krieg C, SprentJ. Homeostatic proliferation and survival of naïve and memory T cells. Eur J Immunol. 2009;39:2088–2094.
     Google Scholar
  56. Kupferschmidt K, Cohen J. Race to find COVID-19 treatments accelerates. Science.2020;367:1412–1413.
     Google Scholar